Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants: ValEAR Trial
Phase of Trial: Phase III
Latest Information Update: 29 Oct 2018
At a glance
- Drugs Valganciclovir (Primary)
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- Acronyms ValEAR
- 20 Oct 2018 Status changed from not yet recruiting to recruiting.
- 07 Jun 2018 Planned End Date changed from 1 Dec 2022 to 1 Jul 2024.
- 07 Jun 2018 Planned primary completion date changed from 1 Dec 2021 to 1 Jul 2022.